Biotech execs vie for a share of obesity drug boom: ‘It’s the early innings’
“We’re really just at the beginning of what’s going to be a very long journey in a very large market,” said a biotech leader chasing the Ozempic boom.
Pharma giants Novo Nordisk and Eli Lilly might’ve led the way into a new era of obesity drugs, but they’re not going to own it, biotech executives say.
“We’re really just at the beginning of what’s going to be a very long journey in a very large market,” said Nancy Thornberry, founding CEO of Kallyope, which is developing its own competing therapies.
What's Your Reaction?
